Oct 12
|
2 Biotech Stocks That Are Screaming Buys This Month
|
Oct 12
|
Cathie Wood's Ark Invest Dumps Over $9M In Moderna Stock — Even With Post-COVID Plans On The Table
|
Oct 11
|
CDC Probes If Bird Flu Mutations Impact Vaccine Stockpile
|
Oct 10
|
Covid-Shot Maker Goes Bankrupt After Trailing Pfizer, Moderna
|
Oct 10
|
GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy
|
Oct 9
|
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
|
Oct 7
|
Low RSV and COVID vaccine usage is in line with investor expectations, but concerning: Jefferies
|
Jul 30
|
Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics
|
Jul 29
|
5 Biotech Stocks to Bet On Bright Industry Prospects
|
Jul 29
|
Exploring Analyst Estimates for Moderna (MRNA) Q2 Earnings, Beyond Revenue and EPS
|
Jul 29
|
RSV vaccine makers vying for market share in second year of shots
|
Jul 26
|
Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?
|
Jul 26
|
Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?
|
Jul 26
|
Moderna Insiders Sell US$3.3m Of Stock, Possibly Signalling Caution
|
Jul 26
|
This Biotech Risk-Taker Created Moderna. Now He’s Harnessing AI.
|
Jul 24
|
Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board
|
Jul 23
|
Why Moderna (MRNA) Dipped More Than Broader Market Today
|
Jun 25
|
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
|
Jun 25
|
Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe
|
Jun 25
|
Exsilio debuts with $82M, pitching a ‘leap’ forward for genetic medicine
|